Developments in hepatitis C therapy during 2000 - 2002

F. Fred Poordad, Tram Tran, Paul Martin

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Hepatitis C virus (HCV) is a human hepatotropic virus with an estimated worldwide prevalence of 170 million cases, including ∼ 4 million cases in the US. It is a major cause of liver disease and is the most common indication for liver transplantation in the US. The majority of infected individuals are eligible for therapy. Since it is difficult to predict who will have progressive disease, those with significant inflammation or fibrosis on histologic examination of liver biopsy are generally offered treatment. The following chapter is an overview of the patent literature during 2000 - mid-2002, and discusses the potential of various treatment modalities for HCV.

Original languageEnglish
Pages (from-to)9-25
Number of pages17
JournalExpert Opinion on Emerging Drugs
Volume8
Issue number1
DOIs
StatePublished - May 1 2003
Externally publishedYes

Fingerprint

Hepatitis C
Hepacivirus
Literature
Patents
Liver Transplantation
Liver Diseases
Fibrosis
Therapeutics
Viruses
Inflammation
Biopsy
Liver

Keywords

  • Antisense oligonucleotide
  • Helicase inhibitors
  • Hepatitis C virus (HCV)
  • Immunomodulators
  • Nucleoside analogue
  • Pegylated interferon
  • Protease inhibitors
  • Ribozymes

ASJC Scopus subject areas

  • Pharmacology

Cite this

Developments in hepatitis C therapy during 2000 - 2002. / Poordad, F. Fred; Tran, Tram; Martin, Paul.

In: Expert Opinion on Emerging Drugs, Vol. 8, No. 1, 01.05.2003, p. 9-25.

Research output: Contribution to journalArticle

Poordad, F. Fred ; Tran, Tram ; Martin, Paul. / Developments in hepatitis C therapy during 2000 - 2002. In: Expert Opinion on Emerging Drugs. 2003 ; Vol. 8, No. 1. pp. 9-25.
@article{dc106856baea4543af797d10edcf51e1,
title = "Developments in hepatitis C therapy during 2000 - 2002",
abstract = "Hepatitis C virus (HCV) is a human hepatotropic virus with an estimated worldwide prevalence of 170 million cases, including ∼ 4 million cases in the US. It is a major cause of liver disease and is the most common indication for liver transplantation in the US. The majority of infected individuals are eligible for therapy. Since it is difficult to predict who will have progressive disease, those with significant inflammation or fibrosis on histologic examination of liver biopsy are generally offered treatment. The following chapter is an overview of the patent literature during 2000 - mid-2002, and discusses the potential of various treatment modalities for HCV.",
keywords = "Antisense oligonucleotide, Helicase inhibitors, Hepatitis C virus (HCV), Immunomodulators, Nucleoside analogue, Pegylated interferon, Protease inhibitors, Ribozymes",
author = "Poordad, {F. Fred} and Tram Tran and Paul Martin",
year = "2003",
month = "5",
day = "1",
doi = "10.1517/14728214.8.1.9",
language = "English",
volume = "8",
pages = "9--25",
journal = "Expert Opinion on Emerging Drugs",
issn = "1472-8214",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Developments in hepatitis C therapy during 2000 - 2002

AU - Poordad, F. Fred

AU - Tran, Tram

AU - Martin, Paul

PY - 2003/5/1

Y1 - 2003/5/1

N2 - Hepatitis C virus (HCV) is a human hepatotropic virus with an estimated worldwide prevalence of 170 million cases, including ∼ 4 million cases in the US. It is a major cause of liver disease and is the most common indication for liver transplantation in the US. The majority of infected individuals are eligible for therapy. Since it is difficult to predict who will have progressive disease, those with significant inflammation or fibrosis on histologic examination of liver biopsy are generally offered treatment. The following chapter is an overview of the patent literature during 2000 - mid-2002, and discusses the potential of various treatment modalities for HCV.

AB - Hepatitis C virus (HCV) is a human hepatotropic virus with an estimated worldwide prevalence of 170 million cases, including ∼ 4 million cases in the US. It is a major cause of liver disease and is the most common indication for liver transplantation in the US. The majority of infected individuals are eligible for therapy. Since it is difficult to predict who will have progressive disease, those with significant inflammation or fibrosis on histologic examination of liver biopsy are generally offered treatment. The following chapter is an overview of the patent literature during 2000 - mid-2002, and discusses the potential of various treatment modalities for HCV.

KW - Antisense oligonucleotide

KW - Helicase inhibitors

KW - Hepatitis C virus (HCV)

KW - Immunomodulators

KW - Nucleoside analogue

KW - Pegylated interferon

KW - Protease inhibitors

KW - Ribozymes

UR - http://www.scopus.com/inward/record.url?scp=0038657769&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038657769&partnerID=8YFLogxK

U2 - 10.1517/14728214.8.1.9

DO - 10.1517/14728214.8.1.9

M3 - Article

C2 - 14610908

AN - SCOPUS:0038657769

VL - 8

SP - 9

EP - 25

JO - Expert Opinion on Emerging Drugs

JF - Expert Opinion on Emerging Drugs

SN - 1472-8214

IS - 1

ER -